In the study, mipsagargin was shown to stabilize tumor progression by specifically targeting PSMA (prostate-specific membrane antigen) expressing endothelial cells that form the HCC-associated vasculature. The gene discussed is FOLH1; the disease is hepatocellular carcinoma.